Volume 5, Issue 4 (1976)
Clinical Research on Psychotropic Drugs and Hyperactivity in Children
In the early 1960’s, subsequent to the thalidomide tragedies, the United States legislature restructured the Food, Drugs and Cosmetics Act to provide the Food and Drug Administration with regulatory power to approve new prescription drugs for marketing only after demonstration of adequate proof of safety and efficacy of the compound. A few years prior to the change in federal regulatory requirements some “new” chemicals were discovered (sometimes serendipitously) which demonstrated significant and potent effects on behavior and were generally considered as psychotropic compounds. The impact of these chemical compounds on the treatment of mental and emotional disorders is well known and not within the scope of this article. The growth of the field of psychopharmacology over the past 14 to 20 years has both reflected and contributed to this impact.
NASP Members Log in
to download article.